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Stress-activated gene × environment interactions may contribute to individual variability in blood pressure reductions
from behavioral interventions. We investigated eﬀects of endothelin-1 (ET-1) LYS198ASN SNP and discriminatory stress
exposure upon impact of 12-week behavioral interventions upon ambulatory BP (ABP) among 162 prehypertensive African
American adolescents. Following genotyping, completion of questionnaire battery, and 24-hour ABP monitoring, participants
were randomized to health education control (HEC), life skills training (LST), or breathing awareness meditation (BAM).
Postintervention ABP was obtained. Signiﬁcant three-way interactions on ABP changes indicated that among ET-1 SNP carriers,
the only group to show reductions was BAM from low chronic stress environments. Among ET-1 SNP noncarriers, under low
chronic stress exposure, all approaches worked, especially BAM. Among high stress exposure noncarriers, only BAM resulted
in reductions. If these preliminary ﬁndings are replicated via ancillary analyses of archival databases and then via eﬃcacy trials,
selection of behavioral prescriptions for prehypertensives will be edging closer to being guided by individual’s underlying genetic
and environmental factors incorporating the healthcare model of personalized preventive medicine.
1.Introduction
Essential hypertension (EH) is a major risk factor for
cardiovascular disease (CVD), and EH incidence among
youth is increasing [1]. African Americans (AAs) experience
a higher prevalence, earlier onset, and greater severity of
EH-related complications than other ethnic groups [2].
From late childhood onward, AAs display increased levels
of resting and ambulatory blood pressure (ABP) compared
to other ethnic groups [3–5]. BP levels are monotonically
associated with future CVD morbidity and mortality [6].
Stage I prehypertensive adults (i.e., SBP/DBP 121–129/81–
84mmHg) have a 40% increased risk and adults with stage
II prehypertension (i.e., SBP/DBP 130–139/85–89mmHg)
are twice as likely to develop CVD compared to those with
optimal BP (<120/<80mmHg) [6–8]. BP percentile ranking
tracksfromlatechildhoodintoadulthood[9–11]placingAA
adolescents with BP between the 50th and 95th percentiles
for age and sex at an increased risk of future EH and CVD
development [9].
EH, like other multifactorial chronic diseases, results
from a complex interplay between an individual’s genetic
underpinnings, lifestyle behaviors, psychosocial factors, and
exposures to various environmental toxins. Over time, this
dynamic interplay eventuates in adverse structural and
functional changes in biological organ systems culminating
in disease manifestation [12, 13]. Among the myriad of
environmental toxins, psychosocial stress such as repeated2 International Journal of Hypertension
exposures to unfair treatment and discrimination associated
with socioeconomic status (SES) inequality and race have
beenimplicatedascontributingtoEH,especiallyamongAAs
[14, 15].
Few pediatric studies have addressed impact of unfair
treatment and discrimination upon BP. Clark and Gochett
[14] found perceived racism to be positively associated
with increased resting SBP among AA youth who reported
a strong intolerance to racist attitudes. Matthews and
colleagues observed unfair treatment to be associated with
increased daytime ABP and night/day ABP ratios in adoles-
cents [16], especially among AA adolescents living in lower
SES neighborhoods [17].
AAs’ BP control abnormalities are frequently associated
with increased vasoconstrictive tone [18–20]. Studies involv-
ing normotensive youth and young adults have shown that
higher levels of resting BP and exaggerated BP responses
to physical and behavioral stressors between AAs and
European Americans (EAs) are often due to higher levels
and/or greater increases in vasoconstrictive tone [21–24].
Associations between psychosocial stress-related factors and
autonomicnervoussystem(ANS)dysregulationindicatethat
excessive endothelial activation also plays a contributory
role [25]. The endothelial and vascular smooth muscle
cells produce endothelin-1 (ET-1), a potent vasoconstrictor,
and endothelium-derived relaxing factor (EDRF; a potent
vasodilator).Imbalancesbetweencirculatingconcentrations,
and/or receptor sensitivity may lead to exacerbations of
vasoconstrictive mediated BP control compounding the
contributions of ANS dysregulation. Among hypertensive
adults and normotensive adolescents and adults, AAs have
exhibited higher plasma ET-1 levels compared to EAs [23,
26–28]. Among normotensive adolescents and young adults,
AAs have shown greater behavioral stress induced plasma
ET-1 increases compared to EAs [23, 26]. A recent study
by Cooper et al. found that among AA adults, greater self-
reported discrimination exposure was associated with higher
ET-1 levels, regardless of SES [29].
The ET-1 gene is localized on chromosome 6, spans
5.5kb, and contains 5 exons and 4 introns. It has been
identiﬁed as a candidate gene for EH and CVD [30]. A
G-to-T transversion predicting a Lysine-Asparagine change
at amino acid 198 (Lys198Asn) single-nucleotide polymor-
phism (SNP) has been associated with increased BP levels
from adolescence to middle age in Japanese EAs and AAs
[31–33]. The Lys198Asn SNP has also been associated with
exaggerated BP reactivity to laboratory stressors, particularly
within the context of background stress-related factors. For
example, in a previous study, T allele carriers from lower
SES backgrounds exhibited the greatest BP increases to a
video game challenge compared to all other subgroups [26].
Rabineau et al. [34] found vasoconstrictive reactivity to
behavioralstresswasthehighestamongT-allelecarrierswith
poor anger management skills. These latter sets of ﬁndings
along with other recent studies [35–37] lend support to the
gene × environment model of stress-induced EH [38, 39].
That is, individuals with genetic susceptibility for EH, who
are exposed to frequent environmental stress and/or other
stress-related potentiating factors (e.g., ineﬀective coping
skills), will be most likely to exhibit the greatest BP stress
reactivity and to eventually develop EH and CVD.
Behavioral stress reduction interventions (e.g., medita-
tion, cognitive behavioral coping skills, etc.) implemented
to improve BP control and other CVD risk factors have
primarily involved adults and quality of research designs
and results have been mixed [40–42]. Rainforth et al.
[42] reviewed 107 stress reduction BP control studies and
conducted a meta-analysis involving 20 studies that were
classiﬁed as well-designed randomized control trials (RCTs).
All but two of the studies involved prehypertensive and
hypertensive adults. Collectively, Transcendental Meditation
(TM) was the only treatment found to signiﬁcantly reduce
resting and/or 24 hour BP.
Far fewer RCTs have been conducted involving youth,
but ﬁndings are promising. Black et al. [43]r e v i e w e d
16 pediatric sitting-meditation RCTs, including breathing
awareness meditation (BAM). Median eﬀect sizes ranged
from 0.16 to 0.29 for physiologic outcomes including
resting and ambulatory BP, heart rate, and total peripheral
resistance [43]. In a recent study, BAM showed signiﬁcantly
greater reductions in ambulatory SBP and sodium excretion
compared to cognitive behavioral skills training (LST) and
health education control (HEC) among a group of AA
prehypertensiveteenagers[44].IncreasedSNSactivationand
increased endothelial system activity (i.e., increased ET-1
levels) have both been shown to increase sodium appetite
[45, 46]. The reduced sodium excretion may be indicative of
reductions in sodium appetite as a result of improvements in
ANS regulation and/or ET-1 activity.
The above review indicates that among stress reduction
RCTs, meditation is consistently associated with signiﬁ-
cant BP reductions. However, even among the meditation
RCTs showing signiﬁcant BP reductions, noticeable inter-
individual diﬀerences have been observed both across and
within studies [41–44, 47]. For example, in Rainforth et al.’s
[42] meta-analysis, the 95% conﬁdence interval for resting
SBP change from 6TM studies was (−2.3 to −7.6mmHg),
with net changes between TM and health education ranging
from −1.1 to −10.7mmHg. Recently, in a group of college
students, Nidich et al. [48] found TM to provide an average
change of −2.0mmHg for resting SBP. A subgroup identiﬁed
as high-risk for EH (i.e., family history of EH) showed a
reduction of −5.0mmHg.
The variability within and across RCTs using meditation
interventions with comparable study samples and adherence
rates may partially be due to combined inﬂuences of hetero-
geneityingeneticsusceptibilityforphysiologicalresponsivity
to stress and propensity for exposure to stressful events. In
genetics, penetrance represents the percentage of cases car-
rying a gene or allele among those displaying the phenotype
ofinterest;expressivity representsvariations ormagnitudein
a phenotype expression. Phenotypes can vary in penetrance
and expressivity by a number of factors including exposure
to environmental factors, allelic variation, and complex gene
by environment interactions [49]. A growing literature is
indicating that higher genetic penetrance and/or expressivity
may adversely impact the degree of beneﬁt obtained from
behavioral as well as pharmacologic programs aimed atInternational Journal of Hypertension 3
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Figure 1: Consort diagram of participant distribution.
improving relevant phenotypes. For example, among smok-
ers who participated in cognitive behavioral interventions
plus pharmacologic smoking cessation therapies, the carriers
of nicotine metabolizing genetic variants, particularly those
from high tobacco smoke exposure-laden environments,
exhibited lower cessation rates and earlier relapse compared
to noncarriers [50]. Similarly, ancillary analyses of the highly
successful Diabetes Prevention Program which involved at-
riskadultsfromobeseladenenvironmentsreceivingplacebo,
metformin, and lifestyle interventions revealed carriers of
the TCF7L2 genetic variant associated with diabetes, had
signiﬁcantly higher incidence of diabetes acquisition during
the study than noncarriers irrespective of the treatment they
received [51].
Thepurpose ofthispreliminary studywastoevaluatethe
potential modulating inﬂuences of genetic variability in the
ET-1 SNP and diﬀerential discrimination-based stress expo-
sure upon changes in ambulatory BP after 12-week expo-
sure to BAM, LST, and HEC among prehypertensive AA
adolescents. We hypothesize that ET-1 carriers will be less
likely to respond to any stress reduction treatment given the
purported propensity of a greater genetic predisposition to
ANS/ET-1 imbalances related to BP control. Following, we
expect ET-1 carriers who report high levels of discrimina-
tion will have the most diﬃculty reducing ambulatory BP
compared to other subgroups due to the combination of
having higher genetic penetrance for an ANS/ET1 imbalance
related to BP control, combined with increased likelihood
of expressivity of the ANS/ET1 imbalance as a result of
high levels of chronic stress exposure. Among the treatment
groups, we hypothesized that BAM would have greater ben-
eﬁcial impact upon ambulatory BP reduction compared to
LST and HEC.
2. Methods
2.1. Subjects. As shown in Figure 1, a total of 1827 students
who would be participating in a semester-long ninth grade
health education class were screened over a ﬁve-year period4 International Journal of Hypertension
todetermineeligibilityforparticipationinthestudy.Eligibil-
ity criteria included having (1) resting SBP between 50th and
95th percentile for age, height and sex [52] on three consec-
utive occasions at school, (2) no history of congenital heart
defect,diabetes,sicklecellanemia,asthma,oranychronicill-
nessorhealthproblemthatrequiresregularpharmacological
treatment,(3)nocurrentorplannedengagementinaformal
exercise, health promotion, or organized sports program
outside of regular school physical education courses, (4)
willingnesstoacceptrandomizationbyschoolintotreatment
groups, (5) being “African American” or “Black”, based on
parental report, (6) never pregnant at any point in the study,
and (7) weighing less than 125kg. The Institutional Review
Boards of the Georgia Health Sciences University and the
Medical University of South Carolina approved the study.
From the 224 eligible participants, genotyping was not
conducted on 30 students. Thirty-two were omitted due to
either missing postevaluation ambulatory BP (n = 23), or
having extreme changes (n = 9) in postintervention 24-hour
SBP (≥3SDs compared to the entire sample; 15mmHg in
either direction).
The distribution of the remaining 162 subjects by
treatment group was: BAM (n = 46, 16 males), LST (n =
59, 24 males), and HEC (n = 57, 20 males). There was
no diﬀerential loss of subjects by treatment group (X2 =
3.65, df = 2, P = .72) and no signiﬁcant diﬀerences
between omitted subjects (n = 62) and the remaining 162
on anthropometric variables and ambulatory BP levels at
baseline (all P’s >. 10).
2.2. Procedures
2.2.1. BP Screening. Three consecutive days of school screen-
ings were conducted. Height was measured by stadiome-
ter and weight by a Detecto CN20 scale (Cardinal Scale
Manufacturing Co., Webb City, Mo, USA). Seated SBP was
recorded using Dinamap 1846SX monitors (Critikon, Inc.,
Tampa, Fla, USA) at minutes 5, 7, and 9 of a 10-minute rest
period. The ﬁrst measurement each day was discarded and
the other two measurements were averaged.
2.2.2. Genotyping. Genomic DNA was extracted from buc-
cal cells using QiaAmp DNA Blood Mini Kits (Qiagen).
Extracted DNA was stored at −80◦C until analyzed. The ET-
1 Lyn198Asn genotype was detected by polymerase chain
reaction (PCR) followed by direct sequence analysis [31].
2.2.3. Ambulatory Blood Pressure Evaluation. Before and
following the intervention, ambulatory SBP and DBP were
recorded for 24 hours. Measurements were recorded every
30 minutes during school, every 20 minutes during self-
reported after school waking hours, and every 30 minutes
during self-reported sleep hours using Spacelabs 90207
monitors (SpaceLabs, Inc., Issaquah, Wash, USA). This
monitor has been previously validated, and ambulatory BP
has been found to be a better predictor of EH than casual
BP [53]. Acceptability of ambulatory readings was based
on previously established criteria including pulse pressure
>20mmHg, DBP ≥ 45mmHg but <100mmHg, SBP >
70mmHg but <180mmHg, HR > 39bpm but <180bpm
[47, 54, 55]. Hourly averages were obtained by averaging
all readings for each clock hour across: daytime (8 a.m.
to 10 p.m.), nighttime (12 a.m. to 6 a.m.), and 24-hour
periods. As in previous studies, to be included in analyses,
hourly averages for SBP and DBP required a minimal of 50%
of total possible evaluations for the respective time period
[47, 54, 55]. The percentage of ambulatory evaluations
across groups for the pre/postinterventions were 78%|80%.
The percentage of ambulatory evaluations by group for
the pre/postinterventions were similar: BAM 78%|81%, LST
78%|79%, and HEC 79%|80%.
2.2.4. Discrimination Assessment. The 9-item everyday dis-
crimination scale (EDS) was used to assess exposure to dis-
crimination [56, 57]. Frequency of encounters was assessed
using a 6-point response format (almost every day, at least
onceaweek,afewtimesamonth,afewtimesayear,lessthan
once a year, and never). The EDS was administered via paper
and pencil during pre- and postintervention evaluations as
part of a battery of psychosocial questionnaires. The EDS has
good internal consistency α = .88 [58], and unidimensional
factor structure [56]. Cronbach’s α was.84 in the current
sample of preintervention data. To investigate inﬂuence
of everyday discrimination, a median split was conducted
on preintervention EDS scores creating low and high EDS
groups. Participants whose score fell on the median were
included in the high EDS group (49% low EDS, 51% high
EDS). The EDS was chosen as a measure of chronic stress
due to its use in several recent pediatric BP association [16,
17, 56] and adult ET-1 association studies [29]. In addition,
the relevance of item content was pertinent to our sample of
adolescent AAs (e.g., and “in your day-to-day life, how often
have you felt threatened or harassed or felt treated with less
respect than other people”).
2.2.5. Interventions. The 12-week intervention was con-
ducted at two high schools during subjects’ regular health
education classes. Students taking these classes do not take
physical education during that semester. Health education
teachers implemented the training and were supervised by
program instructors. Qualitative assessments of the teachers’
programimplementations wereconductedweeklywiththree
Likert scale items (0–4 scale), which assessed thoroughness,
class attentiveness, and enthusiasm. Average instructors
ratings across the 12-week intervention were 3.34 ± 0.26 for
thoroughness, 3.28 ± 0.32 for class attentiveness, and 3.31 ±
0.27forenthusiasm.Therewerenosigniﬁcantdiﬀerencesfor
instructor ratings across the treatment groups (all P’s >. 06).
2.3. Health Education Control (HEC). Weekly health educa-
tion lessons consisted of 50-minute sessions on CV health-
related lifestyle behaviors based upon National Heart, Lung
and Blood Institute guidelines for youth and included
brochures, handouts, videotapes, discussions, and recom-
mendations for increasing physical activity (e.g., walking,
sports, etc.), establishing and maintaining prudent diet (e.g.,International Journal of Hypertension 5
Table 1: Baseline anthropometric characteristics.
Characteristic BAM (n = 46) LST (n = 59) HEC (n = 57)
Age (years) 15.0 ±0.61 5 .0 ±0.71 5 .2 ±0.8
Sex (male/female) 16/30 27/32 25/32
Weight (kg) 66.3 ±15.87 0 .8 ±17.36 6 .8 ±16.5
Height (cm) 163.4 ±8.3 167.5 ±8.6 163.6 ±7.9
BMI (kg/m2)2 4 .8 ±5.32 5 .1 ±5.02 4 .9 ±5.9
LYS198ASN (TT/TG|GG) 14|32 25|34 23|34
EDS (high/low) 22/24 29/30 30/27
24-hour SBP 119.3 ±6.1 119.8 ±6.5 121.8 ±6.8
Daytime SBP 124.0 ±6.4 123.7 ±6.5 126.2 ±7.5
Nighttime SBP 109.1 ±6.6 110.6 ±8.7 111.16 ±8.1
24-hour DBP 68.6 ±5.66 8 .0 ±5.56 9 .3 ±6.2
Daytime DBP 73.4 ±5.97 2 .5 ±5.57 3 .9 ±6.6
Nighttime DBP 57.9 ±6.15 7 .9 ±6.75 8 .7 ±5.7
reducing fat intake). HEC is a basic health education course
and is considered a “usual practice” control group in this
study.
2.3.1. Life Skills Training (LST). Weekly 50-minute sessions
using selected components of the LST program involved
group discussions, passive and active modeling, behavioral
rehearsal, feedback, reinforcement, and behavioral home-
work assignments. The selected program components pro-
vided training in problem-solving skills, reﬂective listening,
conﬂict resolution, and anger management to enhance social
skills, assertiveness, and personal and social competence
[59]. No relaxation or stress reduction techniques were given
to the LST or HEC groups.
2.3.2. Breathing Awareness Meditation (BAM). BAM is exer-
cise one of the Mindfulness-Based Stress Reduction Program
[60].Practiceinvolvesfocusinguponthemoment,sustaining
attention on the breathing process and passively observing
thoughts. The individual sits upright in a comfortable posi-
tion with eyes closed and focuses on diaphragm movements
while breathing in a slow, deep, relaxed manner. Ten-minute
sessions were conducted during health education class and at
home each weekday. On weekends, subjects were instructed
to practice 10-minute sessions twice daily. Self-reported
BAM home practice adherence was 86.6±7.4p e r c e n t .T h e r e
were no signiﬁcant diﬀerences between treatment groups on
in-schoolattendance(F[2, 160] = 2.36,P = .10),HEC81%,
BAM 79%, and LST 88%.
2.4. Data Analysis. Change in values of daytime, nighttime,
and 24-hour SBP, and DBP were compared using a series
of 2 (ET- 1 genotype) by 3 (treatment group) by 2
(EDS group) analyses of variance of change scores (post-
minus preintervention values) that covaried the respective
preintervention values (ANCOVAs). ANOVA analyses were
initially conducted on preintervention anthropometric and
ambulatory BP values. In addition, changes in smoking (i.e.,
average cigarettes per week) and exercise (i.e., days/week
engaged in sweat inducing physical activities) from the
youth risk behavior surveillance system [61], and body
mass index covarying preintervention values were examined
among subgroups. There were no signiﬁcant preintervention
diﬀerences or pre- to post-changes found among the groups
(all P’s >. 10).
To further examine three-way interactions, two-way
interactions and simple main eﬀects across each level of a
thirdvariablewerecalculatedusingthesamepreintervention
covariates. The third variable was chosen on the basis of
the largest F-ratio from the two variables that only had
two levels (i.e., ET-1 genotype or EDS group). Adjusted F-
values (Fadj) were calculated using the mean square for the
analyses of interest divided by the mean square error term
taken from the original model. All subsequent comparisons
following the initial three-way ANCOVA were examined
using Bonferroni adjusted alpha levels.
The series of analyses was originally completed with
general linear modeling using EDS as a continuous variable
which, as anticipated, revealed similar patterns of signiﬁcant
results and conclusions [62]. Given the complex interpre-
tations of the multiple interactions that diﬀerentiate across
groups, the previously described ANCOVA models using
dichotomized median split EDS values are presented.
3. Results
Preintervention anthropometric and ambulatory data are
shown in Table 1. There were no signiﬁcant diﬀerences
between the treatment groups, ET-1 genotype, EDS, or
treatment group by ET-1 genotype by EDS interactions on
any of these parameters (all P’s >. 10).
3.1. Genotyping. Genotype frequencies included 100 par-
ticipants homozygous for the G allele, 52 heterozygous G
and T allele carriers, and 10 homozygous for the T allele.
Frequencies were in Hardy-Weinberg equilibrium (X2 =
.87, df = 1, P = .35) [63]. Due to the small number of
homozygous T allele carriers, participants classiﬁed either as
heterozygous or homozygous for the T alleles were classiﬁed6 International Journal of Hypertension
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Figure 2: Change in ambulatory SBP as a function of everyday discrimination, ET-1 SNP carrier status, and treatment group. Note:
BAM: breathing awareness meditation, HEC: health education control, LST: life skills training. Low: bottom 50th percentile for everyday
discrimination; High: top 50th percentile for everyday discrimination. Values in parentheses indicate n for that subgroup.
as “carriers” (38%), and homozygous G allele carriers were
classiﬁed as “noncarriers” (62%).
3.2. Everyday Discrimination. A two-way (carrier status)
x treatment group ANOVA was conducted on the EDS
pretest scores and veriﬁed no signiﬁcant baseline diﬀerences
due to carrier status, treatment group, or the interaction
between carrier status and genotype (all P’s >. 24). A X2
analyses was used to examine the median split by treatment
group dispersion rate and was not signiﬁcant (P = .88).
Finally, EDS change scores were examined to determine if
any treatment group resulted in signiﬁcant changes to EDS
during the duration of the study. No signiﬁcant changes
in EDS scores by treatment group, ET-1 T allele carrier
status, or their interactions were found (all P’s >. 29).
Correlations between pre- and postintervention EDS scores
were signiﬁcant (r = .59, P<. 001) and indicate that these
scores were stable throughout the study.
3.3. Ambulatory Systolic Blood Pressure
3.3.1. 24-Hour SBP. The omnibus ANCOVA revealed sig-
niﬁcant main eﬀects for ET-1 genotype (F[1, 149] = 7.57,
P<. 01) and treatment group (F[2, 136] = 4.73, P = .01)
w h i c hw e r es u b s u m e dw i t h i na nE T - 1g e n o t y p ext r e a t m e n t
group x EDS group interaction (F[2, 149] = 4.14, P = .02).
Results of the three-way interaction are depicted in Figure 2.
Subsequent analyses examined the two-way interactions and
simple eﬀects for ET-1 carriers and noncarriers separately.
No signiﬁcant interactions or simple main eﬀects for ET-1
carriers were found. Among ET-1 noncarriers, a signiﬁcant
simple main eﬀect for treatment group (Fadj[2, 149] =
4.46, P<. 05) was subsumed within an EDS x treatment
group interaction (Fadj[2, 149] = 4.46, P<. 05). Further
simple eﬀects analyses of treatment eﬀects were separately
conducted across the low and high EDS groups. There
was no treatment eﬀect among the ET-1 noncarriers who
reported low EDS with groups showing comparable 24-hour
SBP changes (range = −2.5 to −2.8mmHg). There was a
signiﬁcant treatment group eﬀect among those from high
EDS backgrounds (Fadj[2, 149] = 8.26, P<. 05). Post
hoc analyses revealed that those who received BAM showed
greaterdeclinethanLSTrecipients(−4.9versus+2.4mmHg,
P<. 05).
3.3.2. Daytime SBP. Signiﬁcant main eﬀects for ET-1 geno-
type (F[2, 146] = 5.38, P = .02) and treatment group
(F[2, 146] = 3.90, P = .02) were subsumed within a three-
way interaction involving the EDS group (F[2, 146] = 4.00,
P = .02). The pattern of the three-way interaction was
similar to that observed for 24-hour SBP (see Figure 2).
Subsequent analyses revealed no signiﬁcant interactions
or simple main eﬀects for ET-1 carriers. Among ET-1
noncarriers, a simple main eﬀect for treatment group was
found (Fadj[2, 146] = 5.32, P<. 05). Post hoc examina-
tion revealed BAM participants showed greater reductions
compared to LST (−4.4 versus +.19mmHg, P<. 05).International Journal of Hypertension 7
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Figure 3: Change in ambulatory DBP as a function of everyday discrimination, ET-1 SNP carrier status, and treatment group. Note.
BAM: breathing awareness meditation, HEC: health education control, LST: life skills training. Low: bottom 50th percentile for everyday
discrimination; High: top 50th percentile for everyday discrimination. Values in parentheses indicate n for that subgroup.
Although not statistically signiﬁcant, the subgroup of ET-1
SNP noncarriers who reported high EDS and received BAM
exhibited the greatest reduction across all subgroups (−5.6
versus range of −3.5 to +2.3mmHg). The only subgroup
amongET-1SNPcarrierstoshowareductionwasthosewith
low EDS that received BAM (−3.6 versus range of −.06 to
+1.95mmHg).
3.3.3. Nighttime SBP. A signiﬁcant main eﬀect for ET-1
genotype (F[1, 130] = 4.68, P = .03) and a trend for
treatmentgroup(F[2, 130] = 3.01, P = .06) were subsumed
within a three-way interaction involving the EDS group
(F[2, 130] = 3.01, P = .05). The pattern was similar to 24-
hour and daytime SBP and is shown in Figure 2. Subsequent
analyses revealed no signiﬁcant interactions or simple main
eﬀects for the high EDS group. Among the low EDS group,
a signiﬁcant main eﬀect for ET-1 carrier status was found
(Fadj[2, 130] = 4.13, P<. 05; noncarriers = −1.7 versus
carriers = +1.8mmHg).
3.4. Ambulatory Diastolic Blood Pressure
3.4.1. 24-Hour DBP. A signiﬁcant treatment group main
eﬀect (F[2, 149] = 4.58, P = .01) was subsumed within
a signiﬁcant three-way interaction (F[2, 149] = 5.38, P =
.01). Figure 3 displays the results of the three-way interac-
tion.Subsequentanalysesrevealednosigniﬁcantinteractions
or simple main eﬀects for ET-1 carriers. Among ET-1 non-
carriers a signiﬁcant two-way interaction between EDS and
treatment group (Fadj[2, 149] = 6.56, P<. 05) and a signif-
icant simple main eﬀect among noncarriers (Fadj[2, 149] =
4.28, P<. 05) were found. Further examination of treatment
groupeﬀectsamongET-1noncarrierswhoreportedlowEDS
was not signiﬁcant and all treatment groups showed similar
reductions in 24-hour DBP. Examination of treatment group
among the ET-1 noncarriers who reported high EDS was
signiﬁcant (Fadj[2, 149] = 8.38, P<. 05). Post hoc analyses
revealed that participants who reported high EDS and
received BAM were signiﬁcantly diﬀerent from those who
received LST (−3.4 versus +2.5mmHg, P<. 05). The pattern
of results is similar to the patterns found across SBP for ET-
1 noncarriers; however, magnitude of change was less for
DBP compared to SBP. For ET-1 carriers, more subgroups
showed a reduction for DBP than SBP. However, those
who received BAM displayed the best results and low EDS
individuals showed better reduction than those high in EDS
(−4.16versus−1.23mmHg).Interestingly,ET-1carrierswho
received BAM and reported low EDS had the best improve-
ment compared to other subgroups including noncarriers
(−4.16mmHgcomparedtorangeof −3.26to+2.50mmHg).
3.4.2. Daytime DBP. A signiﬁcant treatment group eﬀect
(F[2, 146] = 3.26, P = .04) was subsumed within a
three-way interaction (F[2, 146] = 3.52, P = .03) which
is displayed in Figure 3. Subsequent analyses showed no
signiﬁcant interactions or simple main eﬀects for ET-1
carriers. Among ET-1 noncarriers, a signiﬁcant two-way
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(Fadj[2, 146] = 4.77, P<. 05).Subsequentanalysesshowed
no signiﬁcant eﬀects of treatment group among the low EDS
subgroup. A treatment group eﬀect was signiﬁcant among
the high EDS subgroup (Fadj[2, 146] = 6.07, P<. 05)
and post hoc analyses revealed that the BAM subgroup was
signiﬁcantly diﬀerent from the LST subgroup (−3.6 versus
+1.8mmHg, P<. 05).
3.4.3. Nighttime DBP. A signiﬁcant treatment group eﬀect
(F[2, 130] = 3.91, P = .02) was subsumed within a two-way
interaction involving ET-1 genotype and treatment group
(F[2, 130] = 3.33, P = .04). When conducted separately,
no signiﬁcant interactions or simple main eﬀects for ET-
1 noncarriers were found. Among ET-1 carriers, there was
a signiﬁcant treatment group eﬀect (Fadj[2, 130] = 4.45,
P<. 05)andposthocanalysesrevealedthatparticipantswho
received BAM were signiﬁcantly diﬀerent from those who
received LST (−3.6 versus +.74mmHg, P<. 05). Although
a signiﬁcant three-way interaction was not observed for
nighttime DBP, for comparison purposes, the pattern of
changes across ET-1 genotype, treatment group, and EDS
group are displayed in Figure 3.
4. Discussion
In this preliminary study, we hypothesized that individuals
who were ET-1 SNP carriers would have greater diﬃculty
in responding to any of our intervention treatments for
improving ambulatory BP. In the following, we also expected
ET-1SNPcarrierswhoreportedhighlevelsofdiscrimination
to be the most diﬃcult to show ambulatory BP reductions.
Finally, we hypothesized that BAM would have greater
beneﬁcial impact upon ambulatory BP reduction compared
to LST and HEC. Our hypotheses were partially supported.
BAM participants exhibited greater reductions in 24-hour,
daytime and nighttime SBP and DBP compared to the LST
and HEC groups. The modulating inﬂuences of ET-1 SNP
status and EDS were similar across all three ambulatory
indices for SBP and DBP. Among ET-1 SNP carriers, the only
subgroup to show a consistent reduction in SBP and DBP
was BAM recipients who also reported low EDS. In many
cases, the other subgroups showed relatively little reduction
or even increases in BP. Among ET-1 SNP noncarriers, all
three treatments were helpful in reducing BP among those
whoreportedlowEDS.OnlyBAMwasbeneﬁcialinreducing
BP among those who reported high EDS.
The ET-1 Lys198Asn SNP has been shown to play a
signiﬁcant role in vasoconstrictive mediated BP control in
normotensive and hypertensive youth and adults [23, 24, 31,
34, 36]. Our ﬁndings provide further indirect support for
the signiﬁcant role of the ET-1 SNP in BP control among
AAs. For all ambulatory SBP indices, ET-1 carrier status
was a signiﬁcant main eﬀect showing fewer improvements
compared to noncarriers. As noted above, BAM was the
only treatment approach to have success in reducing SBP
among ET-1 SNP carriers and only if they reported low EDS.
It appears that among AAs, behavioral stress BP reduction
programs such as BAM and LST may have diﬃculty in
countering the combination of increased genetic propensity
for stress-activated ANS imbalance/ET-1 activation and high
frequency of environmental stress exposure [23, 24, 26, 34].
Thecognitive skills-based program(LST)onlybeneﬁtted
ET-1 noncarriers and only if they reported low EDS. Partic-
ipants who reported high EDS displayed a slight increase in
ambulatory SBP. Acquisition of the LST skills (e.g., reﬂective
listening, assertiveness without aggressiveness, etc.) may
require the entire 12 weeks. Perhaps implementation of these
newly learned skills in interpersonal conﬂict prone environ-
ments initially results in augmented vigilance and sympa-
thetic/endothelial system activation, rather than reductions
of such. The slight increase in ambulatory SBP among LST
subjects who reported high EDS supports this rationale.
Future studies would beneﬁt from the utilization of repeated
ambulatory BP and biomarker monitoring evaluations (e.g.,
total peripheral resistance, cardiac output, and nocturnal
dipping),alongwithconcomitantselfmonitoringofstressful
encounters, aﬀective states, coping responses, rumination,
and using technological advances in cell phone capabilities.
Although provocative, these results should be interpreted
cautiously. This was an exploratory ancillary analysis of an
RCT, and subgroup cell sizes were relatively small. We exam-
ined potential confounding inﬂuences of sex, BMI, physical
activity,andsmokinganddidnotdetectsigniﬁcantsubgroup
diﬀerences at preintervention or in response to the interven-
tions. The issue of relatively small sample sizes within the
three-way interactions can best be addressed by replication
with larger sample sizes. One approach to consider would be
to capitalize upon archival BP reduction RCTs that involved
stress reduction programs and if not available, we would
aquire DNA samples from the participants. We speculate
thatBPcontrolimprovementsamongBAMparticipantsmay
have been partially a result of improved ANS balance/ET-
1 activity. Several previous ﬁndings showed that BAM also
reduced overnight sodium excretion purportedly through a
reduction in sodium appetite. However, decreased sodium
appetite is a correlate and not an adequate surrogate mea-
sure of ANS/ET-1 activity. The dynamic interplay between
biologicalsystemsrelatedtoBPcontrolwarrantsinclusionof
biological measures of multiple systems and investigation of
the interactions among pathways including the endothelial,
ANS, renin-angiotensin and aldosterone, and HPA axis [25,
38].
As noted earlier, retrospective post hoc analyses of
meditation based BP RCTs involving prehypertensives and
hypertensives (especially those involving AAs) may lend
some support to whether the relationships found in this
study translate to others. Finding similar patterns of ambu-
latory BP changes among ET-1 SNP status and other indices
of chronic stress exposure would augment support for BAM
as a viable approach for inclusion in nonpharmacologic
programs aimed at the prevention of EH and CVD among
certainsubgroupsofindividuals(e.g.,ET-1SNPnoncarriers,
and carriers from low stress environments). The ease of
BAM administration allows it to be practiced in virtual any
setting (i.e., public schools, churches, recreation centers, and
homes) adding to its utility to become part of multifacetedInternational Journal of Hypertension 9
dissemination eﬀorts to help decrease CVD morbidity and
mortality [64].
Unfortunately, our study found none of the behavioral
stress reduction programs were beneﬁcial among ET-1 SNP
carriers who reported high EDS exposure. If our results
are replicated, exploration of alternative behavioral and/or
pharmacologic approaches that target endothelial function
is warranted. Part of the study inclusion requirements was
no current or planned engagement in a formal exercise,
health promotion, or organized sports programs outside of
regular school physical education courses, and the measures
w eu s e df o rp h y s i c a la c t i v i t yw e r en o td i ﬀerently inﬂuenced
by the subgroups. However, behavioral interventions that
are directed speciﬁcally at enhancing high-intensity physical
activity may be beneﬁcial. Aerobic exercise training has
been shown to inhibit vasoconstrictive (e.g., endothelin-1)
and promote vasodilatory (i.e., nitric oxide) mechanisms
related to BP control providing evidence as a potentially
eﬀective therapeutic strategy [65–67]. Speciﬁc to the ET-
1 LYS198ASN SNP, Rankinen et al. [67]f o u n dat w of o l d
higher risk of hypertension among low aerobically ﬁt car-
riers, whereas, aerobically ﬁt carriers’ hypertension risk was
comparable to noncarriers. Additional research is needed to
determineifphysicalactivitycanspeciﬁcallybeneﬁtAAET-1
carriers who report high levels of background stress.
For some individuals, a gene x environment personalized
behavioral intervention approach may not improve BP
control to desired levels. If this occurs, pharmacogenomics-
based primary prevention interventions should be consid-
ered. Several large-scale pharmacologic RCTs have proven
beneﬁcial in reducing onset of EH in prehypertensive adults
[68, 69]. Among ET-1 SNP carriers, an endothelin type A
receptor antagonist may help foster vasodilation-mediated
BP control. In a recent study, Weber et al. found Darusentan,
aselectiveendothelin typeAantagonist,tocontroltreatment
resistant hypertension [70].
5. Conclusions
In summary, the ﬁndings provide preliminary evidence
of some of the underlying contributors that may have
moderated BP reductions but were not examined in pre-
vious meditation RCTs. “One-size ﬁts all” approaches to
primary and secondary preventive health-care are being
replaced with strategies described as preventive, predictive,
personalized,andparticipatory[71].Increasingly,behavioral
and pharmacologic interventions are being tailored on the
basis of individual’s underlying genetic propensities and
environmental factors (e.g., attitudes, stress exposure, etc.).
Personalized medicine is in its infancy, but eventually, via
empirical scrutiny, more eﬃcacious best practice prevention
and treatment approaches will evolve. The end result will
help reduce the incidence of chronic diseases and improve
the quality and longevity of life among those with these
diseases.
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